Breaking Research News from sources other than Breastcancer.org
Comments
-
Wow, great article. I also sporadically took a PPI, maybe three or four times in the two years on Ibrance. I am switching to Xeloda. She did tell me that Pantoprazole could interfere so try Tums or something else. Pantoprazole never made any difference to me. It didn’t really help. Thank you for sharing.
0 -
Whatayear - that is an interesting article. I had to look up PPI to see what it was. I also read that people taking a PPI for a year or longer (not cancer patients) have an increased risk of breaking a hip. Yikes! I don't take PPI, and had to confirm that Rolaids are not a PPI. This is great information to know because a nurse had casually mentioned Protonix, and that I should discuss it with the MO. I just looked it up and it is a PPI. So I am glad to know this information, Whatayear. Thanks!
0 -
In an interview with Targeted Oncology for Metastatic Breast Cancer Awareness Day, O'Regan discussed how the metastatic breast cancer landscape has changed and suggested potential regimens that could further that change.
0 -
Tinkerbell, very interesting.
Have you seen Lumpie?
0 -
Tinkerbell - thank you for posting that article. It was quite honest, but also hopeful. No mention of the ErSO med, though.
0 -
interstitial lung disease is a problem with ADCs used for her2+ tx
Pls share with her2+ peeps so they're aware & vigilant to report symptoms such as shortness of breath.
https://jamanetwork.com/journals/jamaoncology/arti...
Twitter thread by lead author https://twitter.com/PTarantinoMD/status/1448679136...
0 -
LillyisHere: I hope Lumpie is taking a break from these boards. I looked forward to her sharing the latest research information. Until she returns I hope anyone sees anything research worthy please post. Thanks
0 -
I've been reading more about Erso too. Sounds very hopeful except for how slowly things move to trial. I hope we can all keep the conversation going on this and possibly bombard the researchers with questions about it to hopefully get things moving. It really sounds like this could be different than these meds that just string us along for a few more months. Wouldnt it be great if these drugs that just extend life by a few more months than the last one could be put out of business by something that finally looks like more of a cure for this type of breast cancer.
0 -
Elenas401 - Yes, I completely agree about ErSO. I am going to ask my husband to hunt down several people and their email addresses to try to get some answers about clinical trials. He's retired and I am not so he has more time to hunt for information; though I am positive, I am more motivated! haha!
0 -
cross posting from clinical trials thread
https://www.annalsofoncology.org/article/S0923-7534(21)04498-7/fulltext#fig1
Not sure if I agree with everything the article says, but, this very detailed ESMO article gives recommendations for lines of therapyIn ER+ notice that targeted therapies are preferred to chemo for the first 2 lines in most cases. This should help more patients who don't respond and are interested in clinical trials be eligible due to the rigid restrictions of lines of chemo.
ER positive Second-line treatment after CDK 4/6 +ET
- o Selection of second-line therapy (ChT versus further ET-based therapy) should be based on disease aggressiveness, extent and organ function, and consider the associated toxicity profile.
- o Alpelisib/fulvestrant is a treatment option for patients with PIK3CA-mutant tumours (in exons 7, 9 or 20), prior exposure to an AI (± CDK4/6 inhibitors) and appropriate HbA1c levels [I, B; ESMO-MCBS v1.1 score: 2; ESCAT score: I-A].
- o Everolimus/exemestane is an option since it significantly prolongs PFS [I, B; ESMO-MCBS v1.1 score: 2]. Tamoxifen or fulvestrant can also be combined with everolimus [II, B]. If everolimus is used, stomatitis prophylaxis must be used.
- o PARP inhibitor monotherapy (olaparib or talazoparib) should be considered for patients with germline pathogenic BRCA1/2 mutations [I, A; ESMO-MCBS v1.1 score: 4; ESCAT score: I-A] and as an option for those with somatic pathogenic or likely pathogenic BRCA1/2 or germline PALB2 mutations.
- o At least two lines of endocrine-based therapy are preferred before moving to ChT
Dee
0 -
Apparently there is still a dearth of great mouse models that support extensive breast cancer metastasis. Scientists have now created a better model by engineering mice to express the human version of the hormone prolactin, and it supports more extensive metastases- in addition, they showed two different prolactin blocking drugs inhibited lung mets in the new mouse model,
https://www.sciencedaily.com/releases/2021/10/2110...
0 -
Cure-ious Reading that was very enlightening, thank you for sharing. It's interesting that I had a tough time producing milk when I tried to breastfeed any of my three children, yet I ended up with ER+ (97%) BC. I also took birth control pills from 19 to 33 y/o, but it was 21 years later that I was diagnosed.
The other takeaway I had was that I keep seeing each type of BC, take turns as the deadliest. Seven years ago I was diagnosed and told I had "good guy" cancer (oxymoron) because I can take a pill after treatment. Triple negative? We throw chemo at it and see if it works. HER+? Very aggressive, they will try to save your life! Fast forward to today --- Now the women who most die from BC are ER+?
The fact they now have this and at least one possible treatment if it spreads to the lungs, is exciting.
0 -
Curious: Thanks for a sharing that info. I'm wondering why though we just don't hear more everyday about the research into Erso which seems to be the most promising thing on the Horizon for MBC. Whatever it takes to move it along quickly would be good, like the demand grew for HIV drugs years ago.
0 -
I keep googling ErSO to see if there is any news, and I find only articles from July 2021. Here is Bayer's website https://www.bayer.com/en/contact-us I used their "contact us" form to send them an email just now asking about clinical trials.
This page on the Bayer site https://www.bayer.com/en/pharma/access-investigati... show information on how to try a new drug that hasn't gotten FDA approval yet.
0 -
https://clinicaltrials.gov/ct2/show/NCT04708860 This trial is looking at the effects on progression in MBC patients with Hr+ breast cancer when they do nightly prolonged fasting (greater than 13 hours) and moderate exercise 120 minutes per week with 2 weight lifting sessions per week for 12 weeks. Study participants taking either Ibrance or Piqray along with endocrine therapy. Study concludes 9/30/2021 with results July 2022. I will be curious to see the results. I have been doing prolonged nightly fasting most days since 2017 plus more exercise than this study suggests (and it didn't prevent metastasis). Even though it didn't work for me, it's easy to do so I will keep at it.
0 -
Thanks for posting the link, I've just messaged too. Here's hoping
Jools xx
0 -
business wire MBC pipeline report.
Interesting summary
Dee
0 -
I found this post about erso. It has the email address of the CEO.
0 -
Simone,
Thanks for posting. I just emailed him. I would urge everyone else to do so as well. Hopefully, the guy has a heart.
0 -
As have I, Simone and Bev. Thanks for posting!!
0 -
Metavivor.org has some useful information about how to contact your members of Congress. Look at the Stage IV stampede section.
0 -
Thank you, Simone, for posting Werner Baumann's email address. I have emailed him just now and plan to send a new email every day.
0 -
Hopefully it works and he will get things moving.
0 -
Simone, Thanks for posting the ErSO thread. There was a link to a change.org petition further down in the thread:
https://www.change.org/p/bayer-possible-breast-can...
0 -
Here is a recent Nature paper analyzing different types of fasting (namely the nighttime calorie-restricting diet vs the fasting-mimicking diet) in terms of effects on primary and metastatic breast cancer (lung in this case) in mice- they find the nighttime fasting (13+ hours of a water-only fast every evening, as GoKale mentioned) to be the best way to fight cancer cells and improve immune response
https://www.nature.com/articles/s41467-021-26431-4
0 -
Re ERSO, I think it was just an unfortunate press release, in that their enthusiasm they made it sound like a potential cure, but what was reported looked like just a regular "dang good in mice" kind of finding
0 -
Another Nature paper identifies a gene KDM5B as a problem for immunotherapy- this gene is already a target drug companies are working on- inhibition of KDM5B enzyme activity strongly up-regulates immune system attack on solid tumors and helps immunotherapy work
https://www.nature.com/articles/s41586-021-03994-2
Related to that, Cell has an open-access review of all things Immunotherapy-related; if immunology is your thing you will appreciate the scope:
https://www.cell.com/cell/fulltext/S0092-8674(21)01101-6
0 -
Cure-ious - you don't think ErSO will work in humans? I'm willing to try it, and I am going to email the CEO of Bayer every day. I'm asking my family members to email him, too. Plus I signed and shared the change.org petition on facebook.
0 -
GoKale: I think many share your enthusiasm. Dr. Shapiro from U of I said they couldnt believe what they saw, unlike anything they had seen before. More than just "dang good in mice" I saw an article that brought out that they're also testing it in larger animals. I'm glad so many are doing whatever they can to get this moved along faster. Bayer has already invested so much in this it must look promising to them. So many things don't turn out but just think about what it would mean even if it worked almost as good in people. Let's keep hopeful. HIV patients had to to get meds that are keeping them alive today.
0 -
GoKale, I absolutely agree with you - if there's a promising drug, we must push for it to be tried out on humans. I know several drugs that were amazing with mice, and yet they do not reach humans in over 5 years because of many reasons (mostly inaction of institutions, lost interests as ,,it might cost too much", etc.). I am not naive and do not say that what worked in mice might work in humans as well 100% but man, at least we have to try, as mechanism of action is known, toxicities are known (mice!), and probably the only problem that remains is delivery in larger bodies. HIV patients were pushing for their drugs very hard and what they have today is amazing (sure, you cannot compare HIV with C). You never know until you try. Saulius
0
